Consort Medical plc
Consort Medical plc, a leading player in the pharmaceutical and medical device industry, is headquartered in Great Britain. Founded in 1984, the company has established itself as a key innovator in drug delivery systems and medical devices, serving a global market with a strong presence in Europe and North America. Specialising in the development of advanced inhalation devices and other drug delivery technologies, Consort Medical is renowned for its commitment to quality and innovation. Their core products, including the Bespak and Aesica brands, are designed to enhance patient outcomes through precision and reliability. With a robust market position, Consort Medical has achieved significant milestones, including strategic partnerships and a focus on sustainability, solidifying its reputation as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Consort Medical plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Consort Medical plc's score of 23 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Consort Medical plc's reported carbon emissions
In 2023, Consort Medical plc reported a carbon emissions intensity of approximately 3,140 kg CO2e per full-time equivalent (FTE) employee and about 0.02083 kg CO2e emissions per £ of sales. This reflects a slight improvement from 2022, where emissions per FTE were around 3,080 kg CO2e and emissions per £ of sales were approximately 0.01951 kg CO2e. In 2021, the emissions per FTE were significantly higher at about 4,410 kg CO2e. Consort Medical has set ambitious climate commitments, aiming for Net Zero across all scopes (Scope 1, 2, and 3) by 2045, using 2021 as the baseline year. Additionally, the company targets a 42% absolute reduction in Scope 1 and 2 greenhouse gas emissions by 2030. These initiatives demonstrate a proactive approach to addressing climate change and reducing their carbon footprint. The emissions data is cascaded from Consort Medical plc, which is a current subsidiary, indicating a structured approach to sustainability within its corporate family. The company is committed to transparency and accountability in its climate actions, aligning with industry standards for emissions reporting and reduction targets.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Consort Medical plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
